Surrozen Inc (SRZN) - Net Assets
Based on the latest financial reports, Surrozen Inc (SRZN) has net assets worth $-278.15 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($120.71 Million) and total liabilities ($398.86 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible equity quality of Surrozen Inc to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-278.15 Million |
| % of Total Assets | -230.43% |
| Annual Growth Rate | N/A |
| 5-Year Change | -271.16% |
| 10-Year Change | N/A |
| Growth Volatility | 98.63 |
Surrozen Inc - Net Assets Trend (2019–2025)
This chart illustrates how Surrozen Inc's net assets have evolved over time, based on quarterly financial data. See SRZN defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Surrozen Inc (2019–2025)
The table below shows the annual net assets of Surrozen Inc from 2019 to 2025. For live valuation and market cap data, see Surrozen Inc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-187.76 Million | -778.21% |
| 2024-12-31 | $-21.38 Million | -156.36% |
| 2023-12-31 | $37.94 Million | -50.09% |
| 2022-12-31 | $76.00 Million | -30.72% |
| 2021-12-31 | $109.70 Million | +131.96% |
| 2020-12-31 | $47.29 Million | +60.94% |
| 2019-12-31 | $29.39 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Surrozen Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 47200000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.00K | % |
| Other Components | $339.52 Million | % |
| Total Equity | $-187.76 Million | 100.00% |
Surrozen Inc Competitors by Market Cap
The table below lists competitors of Surrozen Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Anhui Huangshan Capsule Co Ltd
SHE:002817
|
$270.05 Million |
|
Liaoning SG Automotive Group Co Ltd
SHG:600303
|
$270.09 Million |
|
Koramco Energy Plus Reit Co Ltd
KO:357120
|
$270.12 Million |
|
Alliance Entertainment Holding Corporation Class A Common Stock
NASDAQ:AENT
|
$270.17 Million |
|
LAVIPHARM S.A. NA EO 1
F:BXA0
|
$269.79 Million |
|
Baiyang Aquatic Group Inc
SHE:002696
|
$269.67 Million |
|
Kaplamin Ambalaj Sanayi ve Ticaret AS
IS:KAPLM
|
$269.66 Million |
|
Biostar Microtech International Corp
TW:2399
|
$269.61 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Surrozen Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -21,380,000 to -187,762,000, a change of -166,382,000.
- Net loss of 242,026,000 reduced equity.
- Share repurchases of 198,000 reduced equity.
- New share issuances of 83,780,000 increased equity.
- Other factors decreased equity by 7,938,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-242.03 Million | -128.9% |
| Share Repurchases | $198.00K | -0.11% |
| Share Issuances | $83.78 Million | +44.62% |
| Other Changes | $-7.94 Million | -4.23% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Surrozen Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $74.71 | $23.25 | x |
| 2020-12-31 | $59.44 | $23.25 | x |
| 2021-12-31 | $46.97 | $23.25 | x |
| 2022-12-31 | $32.83 | $23.25 | x |
| 2023-12-31 | $18.80 | $23.25 | x |
| 2024-12-31 | $-7.29 | $23.25 | x |
| 2025-12-31 | $-25.11 | $23.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Surrozen Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -6960.77%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-49.95%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -82.90% | 0.00% | 0.00x | 1.45x | $-27.30 Million |
| 2020 | -68.98% | 0.00% | 0.00x | 1.31x | $-37.35 Million |
| 2021 | -47.87% | 0.00% | 0.00x | 1.25x | $-63.48 Million |
| 2022 | -36.41% | -221.35% | 0.14x | 1.18x | $-35.27 Million |
| 2023 | -113.46% | -344.34% | 0.27x | 1.21x | $-46.84 Million |
| 2024 | 0.00% | -596.56% | 0.22x | 0.00x | $-61.43 Million |
| 2025 | 0.00% | -6960.77% | 0.04x | 0.00x | $-223.25 Million |
Industry Comparison
This section compares Surrozen Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $131,878,234
- Average return on equity (ROE) among peers: -44.16%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Surrozen Inc (SRZN) | $-278.15 Million | -82.90% | N/A | $269.94 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $85.57 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.69 Million | 20.23% | 0.26x | $328.21 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-12.35 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $203.00 Million | -189.21% | 0.36x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $8.87 Million | -144.74% | 0.54x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $48.18 Million | -23.29% | 0.12x | $7.90 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $17.86 Million | -80.65% | 0.23x | $3.66 Billion |
About Surrozen Inc
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, … Read more